Canada Markets open in 8 hrs 14 mins

IntelGenx Technologies Corp. (IGX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.5800+0.0100 (+1.75%)
At close: 3:12PM EDT
Full screen
Previous Close0.5700
Open0.6000
Bid0.5800 x 0
Ask0.5900 x 0
Day's Range0.5800 - 0.6000
52 Week Range0.1700 - 0.8500
Volume11,848
Avg. Volume27,348
Market Cap89.651M
Beta (5Y Monthly)2.72
PE Ratio (TTM)N/A
EPS (TTM)-0.0770
Earnings DateNov. 10, 2021 - Nov. 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • CNW Group

    IntelGenx Technologies Corp. Virtually Opens the Market

    Horst Zerbe, Chief Executive Officer, IntelGenx Technologies Corp., (the "Company") (TSX: IGX) and his team joined Berk Sumen, Head of TSX Company Services, TMX Group, to celebrate the Company's graduation to Toronto Stock Exchange and open the market.

  • GlobeNewswire

    Patient Screening to Resume in IntelGenx’s ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

    SAINT LAURENT, Quebec, Oct. 12, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”)), a leader in pharmaceutical films, today announced its intention to resume patient screening in the ongoing Montelukast VersaFilm® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”) following Health Canada’s (“HC”) issuance of a No Objection Letter (“NOL”) in response to IntelGenx’s amended Clinical Trial Application. As previ

  • GlobeNewswire

    IntelGenx Receives Final Approval to Graduate to Toronto Stock Exchange

    SAINT LAURENT, Quebec, Oct. 05, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQB: IGXT) (“IntelGenx” or ”the “Company”) announces that it has received final approval to graduate to the Toronto Stock Exchange (the “TSX”) from the TSX Venture Exchange (the “TSXV”). The Company’s shares of common stock (the “Common Shares”), 8% convertible debentures with a maturity date of June 30, 2022 (the “Convertible Debentures”), and share purchase warrants expiring on February 11, 202